Core Viewpoint - The article highlights the rapid growth and potential of the pulse field ablation (PFA) market in China, driven by the increasing prevalence of atrial fibrillation (AF) and advancements in medical technology [5][8]. Group 1: Industry Background - Atrial fibrillation (AF) is the most common type of arrhythmia, characterized by rapid and irregular heartbeats, with a projected patient population of 22.67 million in China by 2025, growing at a compound annual growth rate (CAGR) of 2.85% from 2021 to 2025 [4]. - Traditional ablation methods, including radiofrequency and cryoablation, have significant complications, highlighting the need for safer and more effective solutions [4]. Group 2: Market Potential - The PFA market in China is expected to reach 1.3 billion yuan by 2025, with a CAGR of 43.73%, potentially growing to 16.3 billion yuan by 2032 [5]. - The share of PFA in the overall electrophysiology device market is projected to increase from 8.18% in 2025 to 38.87% in 2032 [5]. Group 3: Technological Advancements - The ALPHATRION® nanosecond pulse field ablation device utilizes a proprietary technology that outputs up to 2000V, offering higher tissue selectivity and reduced risks compared to traditional methods [9]. - The STARTREK™ three-dimensional dielectric imaging navigation system is the first of its kind in China, integrating imaging, mapping, navigation, and damage assessment [10][11]. Group 4: Clinical Developments - The first successful procedure using the integrated system for drug-resistant paroxysmal atrial fibrillation was completed in May 2024 [17]. - A clinical study presented at the HRS annual meeting in May 2024 demonstrated the feasibility and safety of the nanosecond PFA system [18][20]. Group 5: Competitive Landscape - Several domestic companies, including Jinjiang Electronics and Denovo Electrophysiology, have developed PFA systems, with Jinjiang's product being the first approved in December 2023 [24][26]. - The competitive landscape includes various players like Boston Scientific and Medtronic, which have also launched PFA systems with promising clinical outcomes [28][30][33]. Group 6: Company Overview - Jianhu Medical, founded in 2021, focuses on integrated solutions for cardiac electrophysiology, possessing both three-dimensional dielectric mapping technology and nanosecond pulse ablation technology [39].